

Nuri Faruk Aykan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5015691/publications.pdf>

Version: 2024-02-01

48
papers

796
citations

623574

14
h-index

526166

27
g-index

48
all docs

48
docs citations

48
times ranked

1450
citing authors

#	ARTICLE	IF	CITATIONS
1	Red meat and colorectal cancer. <i>Oncology Reviews</i> , 2015, 9, 288.	0.8	105
2	Prognostic Factors in Pancreatic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 547-550.	0.6	93
3	Can Complementary ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1811-1817.	2.8	82
4	Objective response rate assessment in oncology: Current situation and future expectations. <i>World Journal of Clinical Oncology</i> , 2020, 11, 53-73.	0.9	49
5	Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 205-209.	0.6	46
6	Colorectal Cancer in Young Patients: Characteristics and Outcome. <i>Tohoku Journal of Experimental Medicine</i> , 2003, 199, 85-93.	0.5	44
7	Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. <i>Investigational New Drugs</i> , 2008, 26, 567-572.	1.2	37
8	Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 160-171.	1.2	26
9	Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.4	24
10	Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2001, 84, 611-620.	2.9	22
11	Adjuvant Intraperitoneal Chemotherapy With Cisplatin, Mitoxantrone, 5-Fluorouracil, and Calcium Folate in Patients With Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 619-624.	0.6	18
12	A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. <i>Annals of Oncology</i> , 2003, 14, 1106-1114.	0.6	17
13	Prognostic Features and Survival of Inoperable Hepatocellular Carcinoma in Turkish Patients With Cirrhosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 489-493.	0.6	17
14	The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 53-57.	0.6	16
15	Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 47-54.	0.6	15
16	Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 214-220.	0.6	15
17	Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1255-1267.	0.4	14
18	Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 140-146.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Measurement of Serum CA 19-9 May Be More Valuable Than CEA in Prediction of Recurrence in Patients With Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 148-149.	0.6	13
20	Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread?. <i>Melanoma Research</i> , 2006, 16, 259-261.	0.6	13
21	Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?. <i>Medical Oncology</i> , 2013, 30, 660.	1.2	13
22	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. <i>Cancer</i> , 1998, 83, 2475-2480.	2.0	11
23	The role of UFT in advanced gastric cancer. <i>Annals of Oncology</i> , 2008, 19, 1045-1052.	0.6	10
24	Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). <i>Clinical and Translational Oncology</i> , 2013, 15, 403-408.	1.2	9
25	Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients. <i>Tumor Biology</i> , 2014, 35, 11871-11877.	0.8	8
26	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. <i>Turkish Oncology Group. Cancer</i> , 1998, 83, 2475-80.	2.0	8
27	XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer. <i>Oncology</i> , 2007, 73, 298-304.	0.9	7
28	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. <i>BMJ Open</i> , 2020, 10, e027665.	0.8	7
29	Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. <i>BMC Cancer</i> , 2020, 20, 259.	1.1	7
30	A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2011, 2, 19-26.	0.6	7
31	Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 2729-2739.	0.8	6
32	Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. <i>Surgical Oncology</i> , 2018, 27, 485-489.	0.8	6
33	Red meat subtypes and colorectal cancer risk. <i>International Journal of Cancer</i> , 2015, 137, 1788-1788.	2.3	4
34	Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. <i>World Journal of Radiology</i> , 2017, 9, 365-370.	0.5	3
35	The efficacy of a five-drug antiemetic combination during chemotherapy regimens containing cisplatin or cyclophosphamide-doxorubicin. <i>Journal of Pain and Symptom Management</i> , 1993, 8, 126-131.	0.6	2
36	Message-adjusted network (MAN) hypothesis in gastro-entero-pancreatic (GEP) endocrine system. <i>Medical Hypotheses</i> , 2007, 69, 571-574.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 264-272.	0.6	2
38	Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 787-797.	0.4	2
39	Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers. <i>Tumori</i> , 2018, 104, 266-272.	0.6	1
40	The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, , 1.	0.6	1
41	Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an experience of single institute. <i>Medical Oncology</i> , 2007, 24, 384-387.	1.2	0
42	Body Mass Index and Colorectal Cancer. , 2019, , .		0
43	Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 203-203.	0.8	0
44	The diagnostic, predictive, and prognostic role of serum cellular adhesion molecules (VCAM-1, EpCAM) levels in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22001-e22001.	0.8	0
45	Clinical significance of serum vascular cell adhesion molecule-1(VCAM-1) in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-550.	0.8	0
46	Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, e14531-e14531.	0.8	0
47	Prognostic roles of serum NEDD9 levels in patients with gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15103-e15103.	0.8	0
48	Clinical significance of serum claudin-7 levels in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14533-e14533.	0.8	0